Loading clinical trials...
Loading clinical trials...
An Open Label, Randomized, Multicenter, Phase 3 Study to Compare the Immunogenicity, Efficacy and Safety of Gan & Lee Pharmaceuticals Insulin Glargine Injection to Lantus in Adult Subjects With Type 1 Diabetes Mellitus.
Conditions
Interventions
Gan & Lee Insulin Glargine Injection
Lantus®
Locations
85
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Valley Research
Fresno, California, United States
The Rose Salter Medical Research Foundation
Newport Beach, California, United States
California Medical Research Association
Northridge, California, United States
Metabolic Institute of America
Tarzana, California, United States
CMR of Greater New Haven, LLC
Hamden, Connecticut, United States
Start Date
October 31, 2017
Primary Completion Date
August 19, 2019
Completion Date
August 19, 2019
Last Updated
May 14, 2024
NCT07222137
NCT06807190
NCT07160816
NCT04786262
NCT03648918
NCT06748963
Lead Sponsor
Gan and Lee Pharmaceuticals, USA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions